Seeking Alpha

ICOTF
  Ico Therapeutics, Inc. - OTCQX

8/23/2014, 10:49 AM ET
52wk high:  
52wk low:  
EPS:  
PE (ttm):  
Div Rate:  
Yield:  
Market Cap:  
Volume:  
ICOTF vs. ETF Alternatives
Company Description
iCo Therapeutics has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-2008 is targeted for the treatment of vernal or... More
Sector: Financial
Country: Canada